Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas.

ABSTRACT:

Purpose

Claudin 18.2 (CLDN18.2) and fibroblast growth factor receptor 2b (FGFR2b) have recently emerged as promising therapeutic targets for advanced gastric cancer (GC). Before integrating CLDN18.2 and FGFR2b into routine practice, for optimal treatment planning, it is important to consider whether there exists an overlap between these biomarkers.

Materials and methods

We evaluated CLDN18.2 expression in many patients with GC (n=1,538) using tissue microarrays that had been previously used to evaluate FGFR2b overexpression. We investigated the overlap between CLDN18.2 and FGFR2b expression and evaluated the clinicopathological features and prognostic implications of CLDN18.2 expression.

Results

The CLDN18.2 positivity rates at 50% and 75% cutoffs were 34.7% and 24.4%

SUBMITTER: Ahn S 

PROVIDER: S-EPMC12536191 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature